English
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
DUBLIN–(BUSINESS WIRE)–Apr. 10, 2023– Horizon Therapeutics plc (Nasdaq: HZNP) today announced positive and statistically significant topline results from its randomized, double-masked, placebo-controlled Phase 4 clinical trial (NCT04583735) evaluating TEPEZZA for the treatment of adults with chronic TED and low CAS, which is a measure of disease activity. The totality of clinical trial data continues to strongly support the efficacy of TEPEZZA across a broad spectrum of TED patients regardless of disease activity or duration, with a well-established safety profile. TEPEZZA is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of TED – a serious, progressive, debilitating and potentially vision-threatening rare autoimmune disease.1
myBinderRelated Content
-
Genetic Associations of the Thyroid Stimulating Hormone Receptor Gene With Graves’ Diseases and Graves’ ...Graves' disease (GD) is a common thyroid...
-
Psychological Symptoms and Thyroid DisordersPeople with thyroid disorders often have...
-
Association of Radioactive Iodine Treatment With Cancer Mortality in Patients With HyperthyroidismImportance Radioactive iodine (RAI) h...
-
Graves’ Disease Following Immune Reconstitution or Immunomodulatory Treatment: Should We Manage it any Differe...Graves' disease and other disorders of t...
-
Thyroid Glandhttps://www.niddk.nih.gov/-/media/Images...
-
New Therapeutic Horizons for Graves’ HyperthyroidismGraves’ hyperthyroidism is characteriz...
-
Patients’ Perceptions and Views of Surgery and Radioiodine Ablation in the Definitive Management of GravesR...Background: Patients' perceptions and p...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Brought to you by
Supported through an independent
educational grant by
